

IB. AMENDMENTS TOTHE CLAIMS

Please enter the amendments to claim 10, as shown below.

Please enter new claims 28-30, as shown below.

1.-9. (Canceled)

10. (Currently Amended) A method of determining whether an agent is capable of modulating the binding interaction between a ~~polyglutamine expansion comprising~~ protein comprising a polyglutamine expansion and a cellular target of said protein, said method comprising:

(a) contacting a ~~first compound that is~~ said protein or a binding fragment or mimetic thereof with:

(i) said agent; and

(ii) ~~a second protein that is~~ an antibody ~~according to Claim 1 that recognizes a protein comprising a polyglutamine expansion~~ or binding fragment or mimetic thereof, wherein said antibody has greater affinity for said polyglutamine expansion than a 1C2 monoclonal antibody;

(b) detecting the presence of binding complexes comprising said protein and said antibody ~~first and second compounds;~~ and

(c) comparing the results of step (b) with a control;

~~whereby wherein~~ the ability of an agent to modulate the binding interaction between a ~~polyglutamine expansion comprising~~ said protein and said antibody indicates that the ability of said agent to modulate the binding interaction between said protein and a cellular target of said protein a target of said protein is determined.

11. (Original) The method according to Claim 10, wherein said antibody is a monoclonal antibody.

12. (Original) The method according to Claim 10, wherein said agent is a small molecule.

13. (Original) The method according to Claim 10, wherein a plurality of agents are assayed simultaneously.

14. (Withdrawn) A method for detecting the presence of a polyglutamine expansion comprising protein in a sample, said method comprising:
- (a) contacting said sample with an antibody according to Claim 1 or a binding fragment or mimetic thereof; and
 - (b) detecting the presence of a binding complex between said protein and said antibody, binding fragment or mimetic thereof.
15. (Withdrawn) The method according to Claim 14, wherein said polyglutamine expansion comprising protein is a mutant huntingtin protein.
16. (Withdrawn) The method according to Claim 14, wherein said sample is a physiological sample.
17. (Withdrawn) The method according to Claim 14, wherein said antibody is a monoclonal antibody.
18. (Withdrawn) The method according to Claim 14, wherein said antibody, binding fragment or mimetic thereof is stably associated with a solid support.
19. (Withdrawn) A device for use in determining the presence of a polyglutamine expansion comprising sample in a physiological sample, said device comprising:
- an antibody according to Claim 1 or binding fragment or mimetic thereof stably associated with the surface of a solid support.
20. (Withdrawn) The device according to Claim 19, wherein said polyglutamine expansion comprising protein is mutant huntingtin protein.
21. (Withdrawn) The device according to Claim 19, wherein said antibody is a monoclonal antibody.
22. (Withdrawn) A method of modulating the intracellular binding activity of a polyglutamine expansion comprising protein in a cell, said method comprising:

expressing in said cell a nucleic acid encoding an intrabody having the binding characteristics of an antibody according to Claim 1.

23. (Withdrawn) The method according to Claim 22, wherein said intrabody at least comprises the V_H and V_L regions of an antibody according to Claim 1.

24. (Withdrawn) The method according to Claim 22, wherein said polyglutamine expansion comprising protein is a mutant huntingtin protein.

25.-27. (Canceled)

28. (New) The method according to claim 10, wherein said protein is a mutant huntingtin protein.

29. (New) The method according to claim 10, wherein said antibody is attached to a solid support.

30. (New) The method according to claim 10, wherein said protein having a polyglutamine expansion is attached to a solid support.